Y-27632 (dihydrochloride) (Standard)

Y-27632 (dihydrochloride) (Standard) is the analytical standard of Y-27632 (dihydrochloride) . Y-27632 dihydrochloride is an orally active and ATP-competitive ROCK (Rho-kinase) inhibitor (ROCK-I Ki=220 nM; ROCK-II Ki=300 nM) . Y-27632 dihydrochloride shows antiepileptic effects[1][2][3][4].

Product Specifications

CAS Number

[129830-38-2]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Organoid; Reference Standards; ROCK

Type

Reference Standards

Related Pathways

Cell Cycle/DNA Damage; Cytoskeleton; Others; Stem Cell/Wnt; TGF-beta/Smad

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/y-27632-dihydrochloride-standard.html

Purity

99.99

Smiles

O=C([C@@H]1CC[C@]([C@H](N)C)([H])CC1)NC2=CC=NC=C2.[H]Cl.[H]Cl

Molecular Formula

C14H23Cl2N3O

Molecular Weight

320.26

Precautions

H302, H315, H319, H335

References & Citations

[1]Tada S, et al. A selective ROCK inhibitor, Y27632, prevents dimethylnitrosamine-induced hepatic fibrosis in rats. J Hepatol. 2001 Apr;34 (4) :529-36.|[2]Inan S, et al. Antiepileptic effects of two Rho-kinase inhibitors, Y-27632 and fasudil, in mice. Br J Pharmacol. 2008 Sep;155 (1) :44-51.|[3]Xue ZW, et al. Rho-associated coiled kinase inhibitor Y-27632 promotes neuronal-like differentiation of adult human adipose tissue-derived stem cells. Chin Med J (Engl) . 2012 Sep;125 (18) :3332-5.|[4]Ishizaki T, et al. Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol Pharmacol. 2000 May;57 (5) :976-83.